Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CFSAN public calendar

This article was originally published in The Tan Sheet

Executive Summary

CHPA recommends FDA's Center for Food Safety & Applied Nutrition develop a "six-to-nine month public calendar of its planned activities and events," noting "clearly, development of a useful strategic plan would help define this calendar." The Consumer Healthcare Products Association makes the suggestions in follow-up comments to both the June 8 stakeholders meeting on operations issues related to dietary supplements and FDA's May 13 call for comments on the same issue. CHPA also wants CFSAN to provide more notification of upcoming public meetings, noting the typical two-week notice is insufficient to develop comments. On the OTC side, CHPA notes, the association is "typically given six to eight weeks or more to prepare for FDA advisory committees." CHPA notes CFSAN has agreed to help facilitate the transfer of information to its Nonprescription Electronic Library - Dietary Supplements (NEL-DS)

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel